Popular topics to explore
24th Aug · SEBI-Registered Analyst
"Invest like HNIs" by Clovek · 24th Aug
Orchid Pharma posted decent number in Q1 of the FY 27
ORCHPHARMA announced Q1FY27 results
Consolidated Financial Highlights:
Revenue from Operations: For Q1FY27, revenue from operations stood at Rs 30,417.13 lakh, registering a growth of 15.57% YoY compared to Rs 26,318.58 lakh in Q1FY26.…
“Index पर दबाव हो सकता है, लेकिन अवसर खत्म नहीं होते—बस ध्यान सही Share और सही स्तरों पर होना चाहिए।”
आज का Market Outlook / Closing View Nifty: 24,287.65, -78 points (-0.32%) Sensex: 77,728, -281 points (-0.36%) Nifty ne 5th consecutive session decline diya. Main pressure elevated crude oil, Middle-East/U.S.-Iran tensions, IT selling aur F…
Orchid Pharma: Stock Outlook
Orchid Pharma is a leading pharmaceutical company in India, specializing in the manufacture of active pharmaceutical ingredients (APIs) and generic formulations. It serves global markets with a focus on antibiotics, anti-inflammatory, and c…
Orchid Pharma Limited Latest Updates
ORCHPHARMA $178 Million Exblifep Licensing Deal in Russia
On July 8, 2026, Orchid Pharma executed an exclusive licensing agreement with Russian pharmaceutical major Pharmasyntez JSC for its patented hospital antibiotic Exblifep. Under the…
Orchid Pharma Shares Surge on Landmark Russia Licensing Deal for Novel Antibiotic Exblifep
ORCHPHARMA ’s shares surged nearly 9-11% after the company signed a licensing and supply agreement with Russia’s Pharmasyntez JSC for its novel antibiotic Exblifep (cefepime/enmetazobactam).
Under the pact, Pharmasyntez gains exclusive rig…
Orchid Pharma Jumps 11% on Russia Licensing Deal
ORCHPHARMA shares surged 11.39% to ₹1,032.15 after signing a licensing agreement with Russia's Pharmasyntez for its novel antibiotic Exblifep. Pharmasyntez gets exclusive rights to register and market Exblifep in Russia while Orchid manufa…
Orchid Pharma Jumps 13% as Russia Commercialization Deal Boosts Investor Sentiment
ORCHPHARMA Orchid Pharma attracted strong buying interest on July 8, 2026, with the stock surging nearly 13% in morning trade following the announcement of a licensing and supply agreement with Pharmasyntez JSC. The partnership grants Phar…
Pre Market Analysis, Global Cues & Shares in Focus | 08 July, 2026
Global cues have turned slightly weak this morning. US markets closed lower, with Nasdaq falling more than 1% as technology stocks continued to see selling. The Dow and S&P 500 also ended in the red. The bigger concern, however, is crude…
Signs Licensing and Supply Agreement with Pharmasyntez - Orchid Pharma Ltd
Code BSE: 524372 NSE: ORCHPHARMA
Orchid Pharma Signs 1Licensing and Supply Agreement with Pharmasyntez to Commercialize 1Exblifep (Cefepime/Enmetazobactam) in Russia.
Under the agreement, Pharmasyntez will hold the exclusive rights to…
Market Momentum
Market action today is supported by strong momentum across select mid-cap and specialty names, driven by a mix of corporate developments, strategic expansion, and improving earnings visibility. Stocks such as Piramal Pharma are witnessing t…
Orchid Pharma
Company nears US licensing deal for novel antibiotic, talks in advance stage - Moneycontrol
ORCHPHARMA
Orchid Pharma–Dhanuka Merger Creates ₹1,500 Cr Pharma Giant
ORCHPHARMA
Key Highlights
Merger Approval: NCLT clears merger of Dhanuka Laboratories with Orchid Pharma.
Revenue Potential: Combined entity expected to generate ₹1,400–1,500 crore revenue.
EBITDA Outlook: EBITDA projected at ₹200–250…
Orchid Pharma Ltd Latest Updates
ORCHPHARMA Financial Performance (Q3 FY26)The company reported a challenging third quarter ending December 31, 2025. Consolidated revenue stood at ₹212.88 crore, a slight 4.2% increase sequentially but a 5.7% decline year-on-year. Profitab…
Cipla Ltd Regulatory Updates and Stock Reaction
CIPLA USFDA approvals expanded respiratory portfolio (Nintedanib for IPF); partnerships with Orchid Pharma (Cefepime-Enmetazobactam), Sanofi (CNS), Takeda (Vonoprazan).Shares fell 4% on CEO change; trading below key MAs, bearish signals. P…
Orchid Pharma Latest Updates
ORCHPHARMA Merger and Amalgamation StatusThe company’s scheme of amalgamation with Dhanuka Laboratories Limited has reached a critical stage. On March 18, 2026, Orchid Pharma notified stock exchanges that the National Company Law Tribunal…
Orchid Pharma Limited Latest Updates
ORCHPHARMA Consolidated Q3 FY26 Performance
For the quarter ended December 31, 2025, Orchid Pharma reported a consolidated Net Loss of ₹12.61 crore, compared to a profit of ₹20.78 crore in the same period last year. Total revenue for the q…
Global Tensions Shake Markets: Sensex Falls Sharply, Rupee at Record Low
Global Tensions Shake Markets: Sensex Falls Sharply, Rupee at Record Low Indian equity markets saw their steepest weekly fall in over a year, reflecting rising global uncertainty. The BSE Sensex declined 2,368.29 points (2.91%) to close at…
10th Nov · SEBI-Registered Analyst
Currency Grow (CA & SEBI Reg IA Omkar Bhutada) · 10th Nov
💊 Orchid Pharma Ltd – Weekly Chart Analysis
ORCHPHARMA
1️⃣ Structure
The stock was consolidating in a sideways range between ₹630 and ₹850 for nearly 8 months.
After multiple failed attempts, this week’s strong green candle (+15.8%) has closed right at the upper boundary of the…
Orchid Pharma Ltd: Strengthening Presence in Antibiotics and Formulations
ORCHPHARMA Orchid Pharma Ltd is a well-established pharmaceutical company with a strong focus on research, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and formulations. The company has a notable presence in cep…
Cipla vs Superbugs: Leading India’s Antibiotic Resistance Battle
What’s the issue? Antibiotic resistance—or “superbugs”—kills about 4.7 million globally each year, possibly rising to 39 million by 2050 if unchecked. India is severely impacted, making this a public health emergency. Cipla’s Plan: Cipl…
